One Big Step for Bioelectronic Implant Developers Including US Nuclear’s Partner Grapheton
LOS ANGELES, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — On January 29, 2024, an innovative brain implant company reached a new company milestone by surgically implanting electrodes in the brain of their first human subject, thus signaling the opening of a new age and a new industry for companies such as Grapheton. US Nuclear (OTC-QB: UCLE) is proud to be Grapheton’s partner and largest investor, and is incredibly excited about their potential to revolutionize therapies for disabled people of every sort. Grapheton has developed cutting-edge bioelectronic implants aimed at treating various ailments such as cardiac abnormalities, chronic pain, Parkinson’s disease, and hearing loss, taking their technology a step further by using next-generation carbon-based material and multi-modal probes that read both electrical and chemical signals.
Related news for (UCLE)
- US Nuclear Corp. Announces First Quarter 2024 Results
- US Nuclear’s Unparalleled PFAS Monitoring Products in Spotlight as EPA Sets First-Ever Limits on PFAS
- US Nuclear Delivers First Batch of Tritium Monitoring Systems to Nation’s Largest Public Power Company
- US Nuclear’s Overhoff Delivers the Goods to U.S. DOE
- US Nuclear’s Overhoff Branch is Fusion Energy’s Go-To Tritium Monitoring Solution